Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year

Conner Mitchell

Named for the Italian term indicating a piece of music should be played at an upbeat and lively tempo, California-based Vivace Therapeutics seems to have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year

Conner Mitchell

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Pharma's wins and losses in Trump's sprawling executive order on drug prices

In a blow to its obesity pipeline, Pfizer drops oral drug after liver injury case

Exclusive: A small biotech will bring Roche's Angelman drug back to life

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Biotech seed rounds sink to lowest level in years as industry slump drags on

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Vi­vace Ther­a­peu­tics scores $30M Se­ries C to take on­col­o­gy can­di­date for 'Hip­po' path­way to hu­man tri­al next year

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year